Effect of Tetrabenazine on Stroop Interference in HD
- Registration Number
- NCT01834911
- Lead Sponsor
- New York Medical College
- Brief Summary
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2
- Established diagnosis of Huntington disease by movement disorders expert
- Patients currently taking tetrabenazine.
- Patients should not have taken dopamine receptor blocking medication for at least three days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Tetrabenazine withdrawal Tetrabenazine withdrawal Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
- Primary Outcome Measures
Name Time Method Change in Stroop Interference Score 6 hours Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Terence Cardinal Cooke Health Care Center
🇺🇸New York, New York, United States